JP2024520897A5 - - Google Patents

Info

Publication number
JP2024520897A5
JP2024520897A5 JP2023569774A JP2023569774A JP2024520897A5 JP 2024520897 A5 JP2024520897 A5 JP 2024520897A5 JP 2023569774 A JP2023569774 A JP 2023569774A JP 2023569774 A JP2023569774 A JP 2023569774A JP 2024520897 A5 JP2024520897 A5 JP 2024520897A5
Authority
JP
Japan
Prior art keywords
compound
crystal
pharmaceutical composition
ray powder
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/029289 external-priority patent/WO2022241278A1/en
Publication of JP2024520897A publication Critical patent/JP2024520897A/ja
Publication of JP2024520897A5 publication Critical patent/JP2024520897A5/ja
Pending legal-status Critical Current

Links

JP2023569774A 2021-05-14 2022-05-13 ヘモグロビン調節因子の固体形態 Pending JP2024520897A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163188833P 2021-05-14 2021-05-14
US63/188,833 2021-05-14
PCT/US2022/029289 WO2022241278A1 (en) 2021-05-14 2022-05-13 Solid forms of a modulator of hemoglobin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026078723A Division JP2026129958A (ja) 2021-05-14 2026-05-08 ヘモグロビン調節因子の固体形態

Publications (2)

Publication Number Publication Date
JP2024520897A JP2024520897A (ja) 2024-05-27
JP2024520897A5 true JP2024520897A5 (cg-RX-API-DMAC7.html) 2025-05-01

Family

ID=82020064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569774A Pending JP2024520897A (ja) 2021-05-14 2022-05-13 ヘモグロビン調節因子の固体形態

Country Status (13)

Country Link
US (2) US11851424B2 (cg-RX-API-DMAC7.html)
EP (1) EP4337659A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520897A (cg-RX-API-DMAC7.html)
KR (1) KR102968809B1 (cg-RX-API-DMAC7.html)
CN (1) CN117337285A (cg-RX-API-DMAC7.html)
AR (1) AR126649A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022273787B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023021606A2 (cg-RX-API-DMAC7.html)
CA (1) CA3219786A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012156A (cg-RX-API-DMAC7.html)
TW (1) TW202311254A (cg-RX-API-DMAC7.html)
WO (1) WO2022241278A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309517B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024007064A (es) * 2021-12-10 2024-06-20 Global Blood Therapeutics Inc Metodos de administracion de un modulador de hemoglobina.
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP6426694B2 (ja) * 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
PT3880654T (pt) * 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
AR126648A1 (es) * 2021-05-14 2023-11-01 Global Blood Therapeutics Inc Métodos para hacer un modulador de hemoglobina
MX2024007064A (es) * 2021-12-10 2024-06-20 Global Blood Therapeutics Inc Metodos de administracion de un modulador de hemoglobina.

Similar Documents

Publication Publication Date Title
JP2023512175A5 (cg-RX-API-DMAC7.html)
KR102303052B1 (ko) Jak 저해제를 포함하는 제약 조성물
RU2430099C2 (ru) Тозилатная соль терапевтического соединения и ее фармацевтические композиции
JP2022096662A5 (cg-RX-API-DMAC7.html)
JP2023511105A5 (cg-RX-API-DMAC7.html)
JP2022536979A5 (cg-RX-API-DMAC7.html)
ES2199353T3 (es) Nuevos compuestos utiles como agentes neuro-protectores.
RU2624446C2 (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
TWI848241B (zh) 1-(3-氰基-1-異丙基-吲哚-5-基)吡唑-4-羧酸結晶之製備方法及包含彼之醫藥組成物
CN101955440B (zh) 一种阿戈美拉汀新晶型及其制备方法
JP2007522135A5 (cg-RX-API-DMAC7.html)
CN1970547B (zh) 非布司他的晶型及其制备方法
JP2022517842A5 (cg-RX-API-DMAC7.html)
JP2025515671A5 (cg-RX-API-DMAC7.html)
JP2025516683A5 (cg-RX-API-DMAC7.html)
JP2023530785A5 (cg-RX-API-DMAC7.html)
JP2023530786A5 (cg-RX-API-DMAC7.html)
JP2025509830A5 (cg-RX-API-DMAC7.html)
JP2024530315A5 (cg-RX-API-DMAC7.html)
RU2451016C2 (ru) Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида
JP2023528895A5 (cg-RX-API-DMAC7.html)
JP2022518288A5 (cg-RX-API-DMAC7.html)
JP2001521023A (ja) ドフェチリド多形
ES2197144T3 (es) Uso del isomero s(+) puro de fluoxetina para la preparacion de un medicamento contra la migraña.